
Dignify Therapeutics Cleared for Human Trials of Bowel Control Drug
With FDA approval for its Investigational New Drug application, Research Triangle Park-based Dignify Therapeutics is moving its lead candidate, DTI-117, into human testing. The company aims to provide an on-demand, pharmacological solution for neurogenic bowel dysfunction, targeting a November 2026 start for initial volunteer dosing.
























